Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial

Journal of Clinical Pathology

Volumn 58, Issue 11, 2005, Pages 1135-1142

  Jirstrom K ^a   Ryden L ^a   Anagnostaki, L ^a   Nordenskjold B ^b   Stal O ^b   Thorstenson, S ^c   Chebil, G ^d   Jonsson P E ^d   Ferno M ^e   Landberg, G ^a  

^a LUND UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

^c KALMAR COUNTY HOSPITAL   (Sweden)

^d HELSINGBORG HOSPITAL   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MITOSIS INDEX; PATHOLOGY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH; TUMOR VOLUME;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; NEOPLASM STAGING; PREMENOPAUSE; RECEPTORS, ESTROGEN; SURVIVAL ANALYSIS; TAMOXIFEN; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 27644579899     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2005.027185     Document Type: Article

References (35)

1. Early Breast Cancer Trialists Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
2. Ferno M, Baldetorp B, Hatschek T, et al. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. Breast Cancer Res Treat 2000;59:69-76.
3. Bryant J, Fisher B, Dignam J. Duration of adjuvant tamoxifen therapy. J Natl Cancer Inst 2001;30:56-61.
4. Stewart H, Prescott R, Forrest P. Scottish adjuvant tamoxifen trial: a randomised study updated to 15 years. J Natl Cancer Inst 2001;93:456-62.
5. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-9.
6. Elledge RM, Green S, Pugh R, et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a southwest oncology group study. Int J Cancer 2000;89:111-17.
7. Bardou V, Arpino G, Elledge R, et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large databases. J Clin Oncol 2003;21:1973-9.
8. Borg A, Baldetorp B, Fernö M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett 1994;81:137-44.
9. Stal O, Borg A, Ferno M, et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000;11:1545-50.
10. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-46.
11. Grogan M, Tabar L, Chua B, et al. Estimating the benefits of adjuvant systemic therapy for women with early breast cancer. Br J Surg 2001;88:1513-18.
12. Smith D, Howell A, Wagstaff J. Infiltrating lobular carcinoma of the breast: response to endocrine therapy and survival. Eur J Cancer Clin Oncol 1987;23:979-82.
13. Mathieu M, Rouzier R, Llombart-Cussac A, et al. The poor responsiveness of infiltrating lobular breast carcinoma to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 2004;40:342-51.
14. Isola J, Helin H, Helle M, et al. Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis and mitotic count. Cancer 1990;65:1180-4.
15. Ferno M, Baldetorp B, Bendahl P-O, et al. Recurrence-free survival in breast cancer improved by adjuvant tamoxifen - especially for progesterone receptor positive tumors with a high proliferation. Breast Cancer Res Treat 1995;36:23-34.
16. Keshgegian A, Cnaan A. Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 1995;104:42-9.
17. Michels J-J, Duigou F, Marnay J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat 2000;62:117-26.
18. Kallioniemi O-P, Hietanen T, Mattila J, et al. Aneuploid DNA content and high S-phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J Cancer Clin Oncol 1987;23:277-82.
19. Stal O, Skoog L, Rutqvist L, et al. S-phase fraction and survival benefit from adjuvant chemotherapy or radiotherapy of breast cancer. Br J Cancer 1994;70:1258-62.
20. Faneyte I, Schrama J, Peterse J, et al. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 2003;88:406-12.
21. Aas T, Geisler S, Eide G, et al. Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. Eur J Cancer 2003;39:438-46.
22. Petit T, Wilt M, Velten M, et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer treated with neoadjuvant anthracyclin-based chemotherapy. Eur J Cancer 2004;40:205-11.
23. Remvikos Y, Beuzeboc P, Zajdela A, et al. Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst 1989;81:1383-7.
24. Silvestrini R, Daidone M, Mastore M, et al. Cell kinetics as a predictive factor in node-positive breast cancer treated with adjuvant hormone therapy. J Clin Oncol 1993;11:1150-5.
25. Daidone M, Luisi A, Martelli E, et al. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000;82:270-7.
26. Nicholson R, Bouzubar N, Walker K, et al. Hormone sensitivity in breast cancer: influence of heterogeneity of oestrogen receptor expression and cell proliferation. Eur J Cancer 1991;27:908-13.
27. Paradiso A, Tommasi S, Mangia A, et al. Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer. Cancer Res 1990;50:2958-62.
28. International Union against Cancer (UICC). TNM classification of malignant tumours. Berlin-Heidelberg-New York: Springer-Verlag, 1987.
29. Rydén L, Jönsson P-E, Chebil G, et al. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;2:256-64.
30. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991;19:403-10.
31. WHO. International histological classification of tumours. Histologic types of breast tumours. Geneva: World Health Organisation, 1991.
32. Gunther K, Merkelbach-Bruse S, Amo-Takyi B, et al. Differences in genetic alterations between primary lobular and ductal breast cancers detected by comparative genomic hybridization. J Pathol 2001;193:40-7.
33. Korkola J, DeVries S, Fridlyand J, et al. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-75.
34. Li C, Weiss N, Stanford J, et al. Hormone replacement therapy in relation to risk of lobular and ductal breast carcinoma in middle-aged women. Cancer 2000;88:2570-7.
35. Verkooijen H, Fioretta G, Vlastos G, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003;104:778-81.